Consolidative Prostate Radiotherapy in Metastatic Prostate Cancer
ConditionProstate Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexMale
Age18-100
SponsorUniversity Health Network, Toronto
About this trial
This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.
Eligibility criteria
Qualifiers
Histologically-proven prostate cancer
Presence of low-volume or high-volume metastases (high volume defined as the presence of visceral metastases or ≥4 bone lesions with at least 1 lesion beyond the vertebral bodies and pelvis.)
Planned to or receiving systemic treatment ADT +/- ARAT as per physician discretion (Previous chemotherapy allowed if completed more than 6 weeks prior to randomization.)
Planned for EBRT
Disqualifiers
Prior radiotherapy to pelvis
Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
Any condition where radiotherapy is contraindicated
Trial design
Treatments tested in this trial
- Radiotherapy
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
University Health Network, Toronto
Lead sponsor
TerSera Therapeutics LLC
Collaborator
Source ClinicalTrials.gov